Discover and read the best of Twitter Threads about #ash20
Most recents (15)
2020 was rough from an academic standpoint. We couldn’t get clinical or lab research done as planned. I did get some work done. Here are some I feel good about.
1. RCT in Newly diagnosed myeloma of VRd vs KRd. ENDURANCE @myelomaMD @eaonc @TheLancetOncol thelancet.com/journals/lanon…
1. RCT in Newly diagnosed myeloma of VRd vs KRd. ENDURANCE @myelomaMD @eaonc @TheLancetOncol thelancet.com/journals/lanon…
2. RCT of Len vs Observation in Smoldering myeloma. @SagarLonialMD @eaonc @ASCO_pubs ascopubs.org/doi/full/10.12…
3. RCT of Ixa-Rd vs Rd in Newly diagnosed myeloma. TOURMALINE MM-2 @MayoMyeloma @ASH_hematology #ASH20 ash.confex.com/ash/2020/webpr…
In 2020 with @DrOlaLandgren we revealed how Melphalan has strong mutagenic activity on myeloma cells. This can understandably create fear for patients who have undergone transplant, and we have received many questions from them. Here a thread on what we know so far #msmm 👇👇👇
Using whole-exome and genome sequencing data, we can capture the majority of mutations in cancer. Using bioinformatic algorithms we can identify and quantify which mutational processes are involved and responsible for this catalog of mutations (i.e. mutational signatures) 
In 2017 Weinhold and @DrGarethMorgan1 reported a new mutational signature in relapsed multiple myeloma doi.org/10.1182/blood-…. In 2018-2019 with @nickbolli we found the same signature (MM1; rdcu.be/ccTQl and rdcu.be/ccTQm), still without knowing its etiology
#ASH20 IFM 2009 trial results presented by @PerrotAurore
On intent to treat basis early and delayed stem cell transplantation led to identical overall survival at 8 years. Timely given the pandemic situation. See thread on what these results mean. #ASH20VR @ASH_hematology
On intent to treat basis early and delayed stem cell transplantation led to identical overall survival at 8 years. Timely given the pandemic situation. See thread on what these results mean. #ASH20VR @ASH_hematology
Important to note that higher PFS,better MRD- with early transplant, and the fact that not everyone who was randomized to delayed transplant did not manage to affect the probability of staying alive at 8 years one bit. #ASH20
2/
2/
Nevertheless, I still recommend early transplant for most eligible patients for reasons discussed in this thread.
1/ Key data presented #ASH20 from the FORTE, EMN02 and IFM-2009 trials further strengthen the role of transplant in myeloma. FORTE trial also provides key randomized data for dual maintenance. #mmsm #bmtsm Highlights below.
2/ Higher sustained MRD negativity and PFS benefit with KRD-ASCT vs KRD in the FORTE trial presented by Dr. Francesca Gay.
KR maintenance also leads to improved outcomes in all subgroups vs R maintenance alone. #mmsm #ASH20
KR maintenance also leads to improved outcomes in all subgroups vs R maintenance alone. #mmsm #ASH20
3/ IFM 2009 trial: Known higher MRD negativity and better PFS with early vs delayed ASCT.
Even amongst MRD negative group, those in the early SCT group have better PFS.
Similar OS and PFS-2 with early vs. delayed SCT.
3/4th pts in delayed grp received transplant at relapse
Even amongst MRD negative group, those in the early SCT group have better PFS.
Similar OS and PFS-2 with early vs. delayed SCT.
3/4th pts in delayed grp received transplant at relapse
Here are selected abstracts from @MayoClinic @MayoCancerCare being presented at #ASH20
1. CyTOF and TNA seq studies reveal major defects in the cellular tumor immune microenvironment with refractory myeloma. ash.confex.com/ash/2020/webpr… @Taxkourel @myelomaMD @MayoMyeloma
1. CyTOF and TNA seq studies reveal major defects in the cellular tumor immune microenvironment with refractory myeloma. ash.confex.com/ash/2020/webpr… @Taxkourel @myelomaMD @MayoMyeloma
2. Lab studies using salicylates to augment anti tumor effects of selinexor. #ASH20 ash.confex.com/ash/2020/webpr… @JithmaA
3. In patients needing Auto transplant for relapsed DLBCL, interestingly the GCB type had poorer outcome compared to non GCB. #ASH20 ash.confex.com/ash/2020/webpr… @MadihaIqbal13
One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do it?
The update of the IFM trial at #ASH20 addresses this question. ash.confex.com/ash/2020/webpr… #ASH20VR
Thread 👇
The update of the IFM trial at #ASH20 addresses this question. ash.confex.com/ash/2020/webpr… #ASH20VR
Thread 👇
1) Should eligible patients do a transplant: Yes
Two RCTs show an Overall Survival benefit of transplant over chemo alone.
2) Does timing early vs delayed matter?
4 RCTs (including IFM 2009) show similar overall survival regardless of when transplant is done (early vs delayed)
Two RCTs show an Overall Survival benefit of transplant over chemo alone.
2) Does timing early vs delayed matter?
4 RCTs (including IFM 2009) show similar overall survival regardless of when transplant is done (early vs delayed)
The IFM 2009 results show identical overall survival ~60% at 8 years with early or delayed transplant, even though not everyone who is in the delayed transplant group even gets to a transplant. But there are important caveats.
Follow and search #ASH20VR for my commentaries (&critiques) on important myeloma related abstracts during #ASH20.
I have used these personal hashtags selectively to avoid information overload. Check #ASH19VR for last years picks. @MyelomaTeacher @NorthTxMSG @grpetersen1
I have used these personal hashtags selectively to avoid information overload. Check #ASH19VR for last years picks. @MyelomaTeacher @NorthTxMSG @grpetersen1
I started doing personal hashtags at meetings a few years ago for my own selfish reasons. It has worked out great for me. And I’m hoping it’s useful for others.
I tweet a lot at ASH and other Hematology/oncology meetings but won’t add my personal hashtag unless I feel like it’s something very important that I would want to look up in the future.
Aspirin continues to be the most widely used anti-platelet agent, 125 years after its synthesis. But where did it come from - and why do we give it in such weird doses (e.g. 81, 162 & 325 mg) – at least in the United States? #HematologyTweetstory 35 will answer these questions./1
Some lucky ancient person serendipitously discovered that willow bark & leaves relieved pain. Hippocrates used tea made from willow leaf to ease childbirth, while the Egyptian Ebers papyrus (~1500 BCE) mentions willow for aches and pains. (Images: Sermo/Pharmaceutical Journal)/2
In 1763, @royalsociety published a study of dried willow bark for rheumatism, submitted by Edward Stone (1702-1768), a vicar from Chipping Norton in the Cotswolds & fellow @WadhamOxford. Back then a lot of “natural philosophy” (early science) was done by Anglican clergy./ 3
With #ASH20 around the corner, I wanted to share a summary of the major myeloma immunotherapy - CARs, Bispecifics, ADCs trials and #ASH20 abstracts to look out for #mmsm from a recent talk I gave bmj.com/content/370/bm…
I will focus on some of the major drugs in this thread (in the blue boxes). Although I may not be able to cover all of them, the trials I have typed over the image are the ones to watch out for at #ASH20
We will see updates at #ASH20 for cilta-cel (JNJ-4528) and P-BCMA 101. We will see subgroup analyses and correlative data for KarMMa and EVOLVE studies.
Here are my Top 5 #ASH20 @ASH_hematology myeloma abstracts. #ASH20VR
I’ve listed them with links to the full abstract. @mtmdphd @Rfonsi1 @MayoMyeloma @NorthTxMSG @Mohty_EBMT @BldCancerDoc @szusmani @ninashah33 @profghjackson @Phari @PerrotAurore @mvmateos
Thread for countdown👇
I’ve listed them with links to the full abstract. @mtmdphd @Rfonsi1 @MayoMyeloma @NorthTxMSG @Mohty_EBMT @BldCancerDoc @szusmani @ninashah33 @profghjackson @Phari @PerrotAurore @mvmateos
Thread for countdown👇
#5 Allogeneic off-the-shelf CAR-T therapy for myeloma. First in human results with Anti BCMA ALLO-647 shows clinical activity in myeloma.
5 of 15 responses. #ASH20 #ASH20VR @sloan_kettering @Phari @AllogeneTx ash.confex.com/ash/2020/webpr…
5 of 15 responses. #ASH20 #ASH20VR @sloan_kettering @Phari @AllogeneTx ash.confex.com/ash/2020/webpr…
#4 Identification of a potential mechanism for frequent relapses after CAR-T therapy for myeloma: Bi allelic loss of BCMA locus at 16p. Important work. #ASH20 #ASH20VR @DanaFarber @NoopurRajeMD
ash.confex.com/ash/2020/webpr…
ash.confex.com/ash/2020/webpr…
We studied newly diagnosed patients with ET and PV,
reconstructing the lineage history & differentiation trajectories of individual JAK2V617F HSC - here is our preprint will full details #MPNsm
biorxiv.org/content/10.110…
reconstructing the lineage history & differentiation trajectories of individual JAK2V617F HSC - here is our preprint will full details #MPNsm
biorxiv.org/content/10.110…
Our work will be presented by Debra Van Egeren, a grad student @Harvard in an oral abstract @ASH_Hematology #ASH20. This is a team effort across @DanaFarber @BrighamHeme @MGHCancerCenter @df_hcc @BCHStemCell @embl ash.confex.com/ash/2020/webpr…
3. We performed combined single-cell genotyping & transcriptomic profiling on CD34+ enriched BM from newly diagnosed patients with ET and PV, plus whole genome sequencing for lineage tracing of JAK2-mutant HSC.
Ten #ASH20 #MultipleMyeloma abstracts that I think will most inform my clinical practice [𝑻𝒉𝒓𝒆𝒂𝒅] #1/11 #mmsm
1. Another trial [𝑭𝑶𝑹𝑻𝑬] shows meaningful PFS benefit with early ASCT [after KRD], irrespective of cytogenetic risk. (Despite similar early MRD-negative rates in both arms) tinyurl.com/y4re2gpw #mmsm 2/11
2. Long-term follow-up of bb2121 [Ide-Cel] at a median of 15 months: Median PFS➡️𝟗 𝐦𝐨𝐧𝐭𝐡𝐬. At 450 x 106 dosing, ≈80% ≥VGPR and ≈40% CR. Hope to get @FDAOncology approval soon?? tinyurl.com/y4lwcvjy #mmsm 3/11
1/7 Lots to unroll on #ASH20SU #ASH20 #mmsm abstracts, will do in several categories:
TOP TRANSLATIONAL
-ImmunoCell Study (ash.confex.com/ash/2020/webpr…)
-Discordance btwn IFE and MRD (ash.confex.com/ash/2020/webpr…)
@theMMRF @IMFmyeloma @Myeloma_Society @ASH_hematology
TOP TRANSLATIONAL
-ImmunoCell Study (ash.confex.com/ash/2020/webpr…)
-Discordance btwn IFE and MRD (ash.confex.com/ash/2020/webpr…)
@theMMRF @IMFmyeloma @Myeloma_Society @ASH_hematology
2/7 #ASH20SU #ASH20 #mmsm
-Immune ME Changes from MGUS/SMM to active MM (ash.confex.com/ash/2020/webpr…)
-PCL Genome/Transcriptome (ash.confex.com/ash/2020/webpr…)
-Resistance to BCMA Therapy (ash.confex.com/ash/2020/webpr…)
-Immunogenomic heterogeneity in MM (ash.confex.com/ash/2020/webpr…)
-Immune ME Changes from MGUS/SMM to active MM (ash.confex.com/ash/2020/webpr…)
-PCL Genome/Transcriptome (ash.confex.com/ash/2020/webpr…)
-Resistance to BCMA Therapy (ash.confex.com/ash/2020/webpr…)
-Immunogenomic heterogeneity in MM (ash.confex.com/ash/2020/webpr…)
3/7
TOP CLINICAL NON-CART PHASE 1 RRMM #ASH20SU #ASH20 #mmsm
-Teclistamab (ash.confex.com/ash/2020/webpr…)
-MEDI2228 (ash.confex.com/ash/2020/webpr…)
-Talquetamab (ash.confex.com/ash/2020/webpr…)
-BFCR4350A (ash.confex.com/ash/2020/webpr…)
-TNB-383B (ash.confex.com/ash/2020/webpr…)
TOP CLINICAL NON-CART PHASE 1 RRMM #ASH20SU #ASH20 #mmsm
-Teclistamab (ash.confex.com/ash/2020/webpr…)
-MEDI2228 (ash.confex.com/ash/2020/webpr…)
-Talquetamab (ash.confex.com/ash/2020/webpr…)
-BFCR4350A (ash.confex.com/ash/2020/webpr…)
-TNB-383B (ash.confex.com/ash/2020/webpr…)
In December 2020, the 62nd Annual Meeting of @ASH_hematology #ASH20 will be “virtual” – a huge change from the previous 61 meetings. The first ASH annual meeting was in Atlantic City, New Jersey, April 1958. #HematologyTweetstory 29: how did ASH & the annual meeting come about?/1
@BloodJournal came first! In 1941, Henry M. Stratton (1901-1984), a Jewish med student who immigrated to the US from Vienna via Havana in 1938, set up a publishing company called Grune & Stratton with a businessman named Ludwig H. Grunebaum. ("Grune" wasn’t involved for long)./2
Since he'd been a med student & briefly worked for a publisher in Cuba, Stratton mostly started medical journals. One was “Blood: The Journal of Hematology”; later simplified to “Blood.” Stratton needed an editor, so he called a friend at New England Medical Center for advice./3
A hematology-related book suggestion, with some context. Back in 2014, I heard #LawrenceHill speaking on the radio one morning on my way to clinic, about his @CBC #MasseyLectures @UofT on blood's rich symbolism. Mr. Hill grew up as the child of "mixed race" parents in Toronto./1
His parents met in Washington, DC, and moved to Canada in 1955 because at the time it was illegal for them to be married in the Commonwealth of Virginia - prior to the Supreme Court decision on Loving v Virginia in 1967 (real couple below R), the topic of 2016's @lovingthefilm./2
I was Education Program co-chair in 2015 for the @ASH_hematology annual meeting, and I thought: wouldn't it be great if the meeting included a "humanities" talk, by someone like Mr. Hill? So I proposed that to the Executive Committee & they were excited./3 ashondemand.org/Session/107191…
